MET and colorectal carcinoma: For example, MET receptor (ranked 1st) amplification drives the required resistance of CRC to anti‐EGFR therapy,[32] and clinical trials are ongoing to examine EGFR/MET dual inhibition;[19] cell‐surface protein TM4SF1 (ranked 25th) promotion of migration and invasion of CRC cells;[22] CRC overexpression of the genes PRKDC (ranked 8th) and EXO1 (ranked 14th), both of which are involved in DNA repair and recombination[20, 33, 34] and are required for the survival of cancer cells.[35] In addition, the screen revealed TEX10 as a new essential gene in CRC.